Apitegromab — Safety, Research, Risks & Legal Status

Not medical advice. Apitegromab is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	SRK-015; apitegromab (WHO INN)
Category	Peptide (research chemical)
Drug class	Fully human IgG4-lambda monoclonal antibody; selective proform myostatin inhibitor
Developer	Scholar Rock Holding Corp. (NASDAQ: SRRK)
Primary indication	Spinal muscular atrophy (SMA) Types 2 and 3, nonambulatory patients on SMN-targeted background therapy
Regulatory status	BLA under FDA review; PDUFA date September 30, 2026 (not yet approved as of July 2026)
Key selectivity feature	Binds pro-myostatin and latent myostatin only; does not inhibit activin A, BMP9/10, or TGF-beta1, avoiding pan-inhibitor vascular toxicity
Pivotal trial	Phase 3 SAPPHIRE (NCT05156320) - first muscle-targeted therapy with significant motor-function benefit in a pivotal SMA trial
US legal status	Not FDA-approved as of July 2026. A Biologics License Application (BLA) was accepted and is under standard FDA review with a PDUFA action date of September 30, 2026. A prior Complete Response Letter (2025) was issued due to manufacturing facility observations at Catalent Indiana and was unrelated to safety or efficacy data; the resubmission added a second qualified US fill-finish site. Apitegromab is not available for human use outside of clinical trials or compassionate use programs. It is not a dietary supplement and is not legal for general consumer purchase or self-administration in the United States.

What is Apitegromab?

Apitegromab (development code SRK-015) is a fully human IgG4-lambda monoclonal antibody developed by Scholar Rock Holding Corp. that selectively targets the proforms of myostatin - specifically pro-myostatin and latent myostatin - in skeletal muscle. Unlike earlier myostatin inhibitors, apitegromab does not bind mature myostatin or other TGF-beta superfamily members such as activin A, BMP9/10, or TGF-beta1. Its primary clinical program is in spinal muscular atrophy (SMA) Types 2 and 3 in nonambulatory patients who are already receiving approved SMN-targeted therapies (nusinersen or risdiplam). Secondary programs include facioscapulohumeral muscular dystrophy (FSHD) and exploratory investigation in lean-mass preservation during GLP-1-mediated weight loss.

How it works

Apitegromab binds with high selectivity to pro-myostatin and latent myostatin - the inactive precursor forms of the protein - while it is still anchored in the extracellular matrix of skeletal muscle. By occupying these proforms, apitegromab physically blocks the proteolytic cleavage step that would otherwise release and activate mature myostatin. Mature myostatin is a potent inhibitor of muscle fiber growth and differentiation via Smad2/3 signaling; when apitegromab prevents its activation, downstream inhibition of muscle protein synthesis is relieved. The mechanism is muscle-compartment-targeted by design: because pro-myostatin and latent myostatin are concentrated at the sarcolemma and extracellular matrix of skeletal muscle, systemic exposure to the antibody selectively acts where myostatin is expressed. This contrasts with ActRIIB-targeting agents such as ACE-031, which intercept multiple TGF-beta ligands including activin A and caused dose-limiting vascular toxicity (epistaxis, telangiectasia). Apitegromab's selectivity is the basis for its cleaner safety profile observed to date.

Background & history

Myostatin was identified in 1997 as a TGF-beta family member that acts as a master brake on skeletal muscle mass; loss-of-function mutations in animals and rare human cases produce profound muscle hypertrophy. Multiple pharmaceutical attempts to inhibit myostatin followed - including ActRIIB decoy receptors and pan-ligand traps - but these programs were largely halted due to vascular side effects and lack of efficacy in adult populations. Scholar Rock's approach, beginning in the mid-2010s, was to develop a proform-selective antibody that would localize activity to skeletal muscle and avoid off-target suppression of other TGF-beta ligands. SRK-015 entered Phase 1 trials and results were published in 2021. The Phase 2 TOPAZ trial in later-onset SMA Types 2 and 3 provided statistically significant and clinically meaningful motor function data, with 36-month extension data published in Frontiers in Neurology in 2024. The Phase 3 SAPPHIRE trial (NCT05156320) became the first muscle-targeted therapy to demonstrate significant motor function benefit in a pivotal trial in nonambulatory SMA patients already on SMN upregulators. Scholar Rock submitted a BLA, received a Complete Response Letter in 2025 related to a manufacturing site inspection (Catalent Indiana, now part of Novo Nordisk), resolved the issue by qualifying a second US fill-finish facility, and resubmitted. The FDA accepted the resubmission with a PDUFA date of September 30, 2026.

What the research says

Clinical evidence is the strongest in the SMA population. Phase 1 established safety, pharmacokinetics, and pharmacodynamic signal in healthy adults and SMA patients. Phase 2 TOPAZ demonstrated statistically significant improvement on the Hammersmith Functional Motor Scale Expanded (HFMSE) in later-onset SMA Types 2 and 3; long-term 36-month follow-up data supported sustained benefit and continued tolerability. Phase 3 SAPPHIRE is a randomized, double-blind, placebo-controlled pivotal trial (NCT05156320) in nonambulatory SMA Type 2 and 3 patients on background SMN-targeted therapy; this trial provided the efficacy data for the BLA submission. A Phase 2 trial in FSHD (FORGE, NCT07435129) was planned to begin enrollment in mid-2026. An exploratory Phase 2 program to evaluate lean-mass preservation in patients receiving tirzepatide for weight loss is also in early development. Preclinical data in mice showed increased muscle mass and contractile force in healthy animals, prevention of atrophy in dexamethasone models, and improved muscle mass, function, and bone volume in SMA mouse models when combined with SMN upregulation. Human data outside SMA are not yet available.

Reported effects

Inhibits myostatin activation selectively in skeletal muscle by blocking proteolytic processing of pro-myostatin and latent myostatin
Demonstrated statistically significant improvement in motor function (HFMSE scores) in nonambulatory SMA Types 2 and 3 patients on background SMN-targeted therapy in Phase 2 and Phase 3 trials
36-month Phase 2 TOPAZ extension data showed sustained motor function benefit and continued tolerability
Preclinical (murine) data: increased muscle mass and contractile force in healthy animals; attenuated muscle atrophy in steroid-induced atrophy models
Preclinical (murine SMA model): combined with SMN upregulation, improved muscle mass, contractile function, and bone volume, suggesting possible fracture-risk reduction - human confirmation pending
No epistaxis, telangiectasia, or gum bleeding observed - the dose-limiting vascular toxicity profile associated with pan-myostatin/activin inhibitors was absent
Exploratory programs for FSHD and lean-mass preservation during GLP-1-mediated weight loss are early-stage; no efficacy data available in those populations

Dosing & administration (informational)

Literature from Phase 1 through Phase 3 trials describes IV infusion dosing at multiple weight-based and fixed-dose cohorts administered on a periodic schedule. Published pharmacokinetic and pharmacodynamic data are available in primary trial publications (see PubMed search terms below). This information is provided for scientific reference only and does not constitute a dosing protocol. Specific dose selection for any patient is a clinical decision requiring specialist evaluation; consult a treating neurologist or neuromuscular disease specialist.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Generally well tolerated in Phase 1, 2, and 3 trials; no deaths or serious adverse events attributed to apitegromab were reported
Most common treatment-emergent adverse events (TOPAZ Phase 2): headache (24.1%), pyrexia (22.4%), upper respiratory tract infection (22.4%), cough (22.4%), nasopharyngitis (20.7%) - frequency typical of the underlying SMA population
Vascular adverse effects (epistaxis, telangiectasia, gum bleeding) notably absent - differentiating it from earlier pan-myostatin inhibitors targeting ActRIIB
Long-term safety characterized out to 36 months in TOPAZ extension; no new safety signals identified over follow-up
Population studied is patients with SMA on background SMN therapies; safety profile in healthy adults or other disease populations is less well characterized
As a monoclonal antibody, immunogenicity (anti-drug antibody formation) is a theoretical risk common to all biologics; specific incidence data should be reviewed in primary publications
Not evaluated outside controlled clinical settings; no data on use in pregnancy, pediatric populations beyond SMA trials, or in combination with agents other than nusinersen and risdiplam

Drug & supplement interactions

N
o
f
o
r
m
a
l
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
h
a
v
e
b
e
e
n
p
u
b
l
i
s
h
e
d
i
n
t
h
e
o
p
e
n
l
i
t
e
r
a
t
u
r
e
a
s
o
f
J
u
l
y
2
0
2
6
.
I
n
c
l
i
n
i
c
a
l
t
r
i
a
l
s
,
a
p
i
t
e
g
r
o
m
a
b
w
a
s
c
o
-
a
d
m
i
n
i
s
t
e
r
e
d
w
i
t
h
n
u
s
i
n
e
r
s
e
n
(
S
p
i
n
r
a
z
a
)
a
n
d
r
i
s
d
i
p
l
a
m
(
E
v
r
y
s
d
i
)
-
t
h
e
S
M
N
-
t
a
r
g
e
t
e
d
t
h
e
r
a
p
i
e
s
s
t
a
n
d
a
r
d
i
n
S
M
A
-
w
i
t
h
o
u
t
r
e
p
o
r
t
e
d
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
i
n
t
e
r
a
c
t
i
o
n
s
,
w
h
i
c
h
i
s
e
x
p
e
c
t
e
d
g
i
v
e
n
t
h
e
d
i
f
f
e
r
e
n
t
m
e
c
h
a
n
i
s
m
s
a
n
d
m
e
t
a
b
o
l
i
c
p
a
t
h
w
a
y
s
(
m
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
i
e
s
a
r
e
n
o
t
h
e
p
a
t
i
c
a
l
l
y
m
e
t
a
b
o
l
i
z
e
d
v
i
a
C
Y
P
e
n
z
y
m
e
s
)
.
T
h
e
e
x
p
l
o
r
a
t
o
r
y
l
e
a
n
-
m
a
s
s
p
r
o
g
r
a
m
w
i
l
l
c
o
-
a
d
m
i
n
i
s
t
e
r
w
i
t
h
t
i
r
z
e
p
a
t
i
d
e
;
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
f
r
o
m
t
h
a
t
p
r
o
g
r
a
m
a
r
e
n
o
t
y
e
t
a
v
a
i
l
a
b
l
e
.
A
s
w
i
t
h
a
n
y
b
i
o
l
o
g
i
c
,
c
o
n
c
u
r
r
e
n
t
i
m
m
u
n
o
s
u
p
p
r
e
s
s
i
o
n
c
o
u
l
d
t
h
e
o
r
e
t
i
c
a
l
l
y
a
f
f
e
c
t
i
m
m
u
n
o
g
e
n
i
c
i
t
y
a
n
d
a
n
t
i
b
o
d
y
r
e
s
p
o
n
s
e
,
b
u
t
t
h
i
s
h
a
s
n
o
t
b
e
e
n
s
p
e
c
i
f
i
c
a
l
l
y
c
h
a
r
a
c
t
e
r
i
z
e
d
f
o
r
a
p
i
t
e
g
r
o
m
a
b
.

Who should avoid it

Self-administration outside clinical trial or compassionate use settings - no legitimate non-clinical supply exists
Use without SMN-targeted background therapy in SMA (clinical benefit was established in patients already receiving nusinersen or risdiplam; monotherapy data are limited)
Assuming safety data from the SMA population generalizes to other indications or healthy individuals - lean-mass and FSHD programs have not reported efficacy or safety data
Conflating apitegromab with earlier pan-myostatin inhibitors (e.g., ACE-031, bimagrumab) - mechanism and safety profile are distinct
Procurement from non-clinical or grey-market sources, which carry unknown identity and sterility risks for an IV biologic

How it is commonly combined

No stacking data exist outside the clinical context of co-administration with SMN-targeted SMA therapies (nusinersen, risdiplam). An exploratory Phase 2 program pairing apitegromab with tirzepatide for lean-mass preservation is in early development as of mid-2026 but has not reported results. All co-administration scenarios are investigational and managed within controlled trial protocols.

Legal & regulatory. Not FDA-approved as of July 2026. A Biologics License Application (BLA) was accepted and is under standard FDA review with a PDUFA action date of September 30, 2026. A prior Complete Response Letter (2025) was issued due to manufacturing facility observations at Catalent Indiana and was unrelated to safety or efficacy data; the resubmission added a second qualified US fill-finish site. Apitegromab is not available for human use outside of clinical trials or compassionate use programs. It is not a dietary supplement and is not legal for general consumer purchase or self-administration in the United States.

Quality & harm reduction

A
p
i
t
e
g
r
o
m
a
b
i
s
a
n
i
n
v
e
s
t
i
g
a
t
i
o
n
a
l
b
i
o
l
o
g
i
c
p
r
o
d
u
c
e
d
u
n
d
e
r
G
M
P
c
o
n
d
i
t
i
o
n
s
b
y
S
c
h
o
l
a
r
R
o
c
k
i
n
p
a
r
t
n
e
r
s
h
i
p
w
i
t
h
C
a
t
a
l
e
n
t
I
n
d
i
a
n
a
(
N
o
v
o
N
o
r
d
i
s
k
)
a
n
d
a
s
e
c
o
n
d
q
u
a
l
i
f
i
e
d
U
S
f
i
l
l
-
f
i
n
i
s
h
f
a
c
i
l
i
t
y
.
I
t
i
s
a
v
a
i
l
a
b
l
e
o
n
l
y
w
i
t
h
i
n
c
l
i
n
i
c
a
l
t
r
i
a
l
s
o
r
c
o
m
p
a
s
s
i
o
n
a
t
e
u
s
e
f
r
a
m
e
w
o
r
k
s
.
T
h
e
r
e
i
s
n
o
l
e
g
i
t
i
m
a
t
e
p
a
t
h
w
a
y
f
o
r
c
o
n
s
u
m
e
r
o
r
r
e
s
e
a
r
c
h
-
c
h
e
m
i
c
a
l
p
r
o
c
u
r
e
m
e
n
t
;
a
n
y
m
a
t
e
r
i
a
l
m
a
r
k
e
t
e
d
o
u
t
s
i
d
e
c
l
i
n
i
c
a
l
c
h
a
n
n
e
l
s
w
o
u
l
d
b
e
o
f
u
n
k
n
o
w
n
i
d
e
n
t
i
t
y
,
p
u
r
i
t
y
,
a
n
d
s
t
e
r
i
l
i
t
y
.
M
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
i
e
s
r
e
q
u
i
r
e
c
o
l
d
-
c
h
a
i
n
s
t
o
r
a
g
e
,
s
t
e
r
i
l
e
p
r
e
p
a
r
a
t
i
o
n
,
a
n
d
I
V
o
r
S
C
a
d
m
i
n
i
s
t
r
a
t
i
o
n
u
n
d
e
r
c
l
i
n
i
c
a
l
s
u
p
e
r
v
i
s
i
o
n
-
s
e
l
f
-
a
d
m
i
n
i
s
t
r
a
t
i
o
n
i
s
n
o
t
a
p
p
r
o
p
r
i
a
t
e
.

Safer, legal alternative we recommend

Creatine Supreme. For supporting muscle mass and strength, creatine monohydrate is the most evidence-backed legal option, with decades of safety data - ours ships from the Peptropix line.

See our recommended pick

Find Apitegromab →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What makes apitegromab different from earlier myostatin inhibitors like ACE-031?

Earlier agents such as ACE-031 (a soluble ActRIIB decoy receptor) blocked a broad range of TGF-beta family ligands including activin A, BMP9, and BMP10 in addition to myostatin. This produced dose-limiting vascular side effects - epistaxis, telangiectasia, and gum bleeding - that halted those programs. Apitegromab targets only the proforms of myostatin (pro-myostatin and latent myostatin) while they are still tethered to skeletal muscle extracellular matrix, and does not bind the other ligands. In clinical trials to date, vascular adverse events have been absent, supporting the hypothesis that the selectivity difference is pharmacologically meaningful.

Is apitegromab approved and available?

No, as of July 2026. Scholar Rock submitted a BLA to the FDA and the agency accepted it for standard review with a PDUFA action date of September 30, 2026. A 2025 Complete Response Letter was issued due to manufacturing inspection findings at Catalent Indiana (not related to the drug's safety or efficacy data); Scholar Rock resolved this by qualifying a second US fill-finish facility and resubmitted. Pending FDA decision, US commercial launch is anticipated in Q4 2026 if approved. The drug is currently available only through clinical trials or compassionate use programs.

Why is apitegromab used alongside SMN-targeted therapies rather than alone?

SMA is caused by insufficient SMN protein, and SMN-targeted treatments (nusinersen, risdiplam, onasemnogene abeparvovec) address that root cause. However, even with SMN restoration, many patients - particularly those with later-onset or nonambulatory SMA Types 2 and 3 - have experienced significant prior motor neuron loss and muscle atrophy. Apitegromab targets a separate biological pathway by relieving myostatin-mediated inhibition of muscle growth, potentially allowing the remaining motor units to drive greater muscle mass and function. The Phase 3 SAPPHIRE trial enrolled patients specifically on background SMN therapy, and that combination is the context for which clinical evidence exists.

What does the 36-month TOPAZ extension data show?

The long-term extension of the Phase 2 TOPAZ trial, with results published in Frontiers in Neurology in 2024, showed that the motor function benefits observed in the core trial were sustained over 36 months of follow-up. The safety profile remained consistent with earlier observations - headache, pyrexia, upper respiratory infection, cough, and nasopharyngitis were the most common adverse events, and no vascular toxicity or new safety signals emerged. The data supported the tolerability profile used in the BLA submission.

Can apitegromab be used for muscle building or body composition in healthy people?

There are no human data supporting use in healthy individuals for body composition or performance purposes. Preclinical mouse studies showed increased muscle mass and force in healthy animals, and an exploratory Phase 2 program is investigating lean-mass preservation during tirzepatide-mediated weight loss, but those results are not yet available. Apitegromab is an unapproved investigational biologic; it has no legitimate non-clinical supply chain, requires IV administration under medical supervision, and is not appropriate for use outside of clinical trials. No safety data exist in healthy adult populations.

What should I ask my doctor about apitegromab if I have SMA?

Peptropix does not provide medical advice. If you or a family member has SMA and you are interested in apitegromab, the appropriate step is to consult a neuromuscular disease specialist or SMA-focused center of excellence. They can review current clinical trial enrollment status (ClinicalTrials.gov NCT05156320 and related studies), compassionate use options, and - if the drug receives FDA approval by its PDUFA date - anticipated commercial availability and eligibility criteria.

References & further reading

PubMed: "apitegromab spinal muscular atrophy" OR "SRK-015 myostatin" - yields Phase 1 (2021), Phase 2 TOPAZ, preclinical safety/toxicokinetics, and 36-month extension publications
ClinicalTrials.gov NCT05156320 - SAPPHIRE Phase 3, apitegromab in SMA Types 2 and 3
ClinicalTrials.gov NCT03921528 - TOPAZ Phase 2 SMA; NCT05626855 - TOPAZ long-term extension
ClinicalTrials.gov NCT07435129 - FORGE Phase 2, apitegromab in facioscapulohumeral muscular dystrophy (FSHD)
Frontiers in Neurology (2024) - 36-month TOPAZ extension safety and efficacy data; Neurology (2024) - Phase 3 SAPPHIRE primary results